Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
EHC 2024
Programm
Poster
Suche
DE
Zurück
Poster session
PoS 4
ePoster 01
Termin
Datum:
06.12.
Zeit:
12:30
–
13:30
Ort / Stream:
ePoster station 1
Programm
ePoster
P250
Real-life experience of rimegepant in episodic migraine
Celia Santillana Avila (Granada, ES)
ePoster
P251
Anti-CGRP antibodies in patients with migraine and autoimmune disease with concomitant immunosuppressants/immunomodulators treatment: interactions, safety and effectiveness
Noelia Guerrero Carmona (Sevilla, ES)
ePoster
P252
Response to eptinezumab in chronic cluster headache – a case report
Jorge Madera Fernandez (Santander, ES)
ePoster
P253
Characteristics of patients prescribed rimegepant vs. all patients seeking migraine care via telemedicine
Motomori Lewis (New York, US)
Lucy Abraham (Tadworth, GB)
ePoster
P254
Is Erenumab effective and safe in long term migraine treatment? A three-years observational study
Elisa Maria Bruno (Bologna, IT)
ePoster
P255
A 3-year migraine management with anti-CGRP monoclonal antibodies: an intention-to-treat analysis of real-world evidence
Elena Mazzotta (Pavia, IT)
ePoster
P256
The effect of 9-months fremanezumab preventive treatment on the triptan response and on the incidence of triggers and prodromal symptoms in patients with HFEM
Emmanouil V. Dermitzakis (Thessaloniki, GR)
ePoster
P257
Multi-parametric efficacy assessment of Eptinezumab in patients with chronic migraine and medication overuse headache – early results from a third level headache center
Danilo Antonio Montisano (Milan, IT)
ePoster
P258
Quarterly fremanezumab: assessing migraine relief and patient satisfaction
Cristina Trevino-Peinado (Leganés, ES)
ePoster
P259
Refractory chronic migraine: no symptomatic relief after 20 preventive medications
Stefanie Moreira (Braga, PT)
v1.20.0
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz